Viridian Therapeutics Valuation
| 0K1R Stock | 15.30 0.05 0.33% |
At this time, the company appears to be overvalued. Viridian Therapeutics has a current Real Value of USD13.94 per share. The regular price of the company is USD15.3. Our model measures the value of Viridian Therapeutics from inspecting the company fundamentals such as Return On Equity of -0.48, shares outstanding of 30.84 M, and Shares Owned By Institutions of 99.88 % as well as reviewing its technical indicators and probability of bankruptcy.
Enterprise Value 741.5 M | Price Sales 11.4966 |
Overvalued
Today
Please note that Viridian Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Viridian Therapeutics is based on 3 months time horizon. Increasing Viridian Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Viridian stock is determined by what a typical buyer is willing to pay for full or partial control of Viridian Therapeutics. Since Viridian Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Viridian Stock. However, Viridian Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.3 | Real 13.94 | Hype 15.3 | Naive 15.05 |
The intrinsic value of Viridian Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Viridian Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Viridian Therapeutics helps investors to forecast how Viridian stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Viridian Therapeutics more accurately as focusing exclusively on Viridian Therapeutics' fundamentals will not take into account other important factors: Viridian Therapeutics Cash |
|
Viridian Therapeutics Total Value Analysis
Viridian Therapeutics is presently projected to have takeover price of 741.51 M with market capitalization of 2.84 T, debt of 21.09 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Viridian Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
741.51 M | 2.84 T | 21.09 M |
Viridian Therapeutics Investor Information
About 100.0% of the company shares are owned by institutions such as pension funds. The company recorded a loss per share of 5.14. Viridian Therapeutics had not issued any dividends in recent years. The entity had 0.066667:1 split on the 13th of November 2020. Based on the key indicators related to Viridian Therapeutics' liquidity, profitability, solvency, and operating efficiency, Viridian Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Viridian Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Viridian Therapeutics has an asset utilization ratio of 0.0407 percent. This implies that the Company is making USD4.07E-4 for each dollar of assets. An increasing asset utilization means that Viridian Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Viridian Therapeutics Ownership Allocation
Viridian Therapeutics maintains a total of 30.84 Million outstanding shares. The majority of Viridian Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Viridian Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Viridian Therapeutics. Please pay attention to any change in the institutional holdings of Viridian Therapeutics as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.Viridian Therapeutics Profitability Analysis
The company reported the revenue of 302 K. Net Loss for the year was (269.95 M) with loss before overhead, payroll, taxes, and interest of (237.95 M).About Viridian Therapeutics Valuation
The stock valuation mechanism determines Viridian Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Viridian Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Viridian Therapeutics. We calculate exposure to Viridian Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Viridian Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 302 K | 317.1 K |
Additional Tools for Viridian Stock Analysis
When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.